Table 2.
Incidence of hepatocellular carcinoma (HCC) according to lipid profile classification.
| HCC Cases (n) | Incidence of HCC (100,000 Person-(100,000 Person-Years) |
Crude HR (95% CI) |
Adjusted HR a (95% CI) |
p-Value | |
|---|---|---|---|---|---|
| TC (mg/dL) | |||||
| Q1 (0–169) | 10,839 | 69.22 | 1 (reference) | 1 (reference) | |
| Q2 (170–191) | 6891 | 43.98 | 0.64 (0.62–0.66) | 0.61 (0.59–0.63) | <0.0001 |
| Q3 (200–214) | 5170 | 33.94 | 0.49 (0.47–0.51) | 0.46 (0.44–0.47) | <0.0001 |
| Q4 (≥215) | 3991 | 25.84 | 0.37 (0.36–0.39) | 0.36 (0.34–0.37) | <0.0001 |
| TG (mg/dL) | |||||
| Q1 (0–72) | 6711 | 43.17 | 1 (reference) | 1 (reference) | |
| Q2 (73–105) | 7969 | 51.24 | 1.19 (1.15–1.23) | 0.95 (0.91–0.99) | <0.0001 |
| Q3 (106–157) | 7078 | 45.72 | 1.06 (1.02–1.09) | 0.77 (0.72–0.82) | <0.0001 |
| Q4 (≥158) | 5133 | 33.26 | 0.77 (0.74–0.80) | 0.59 (0.54–0.65) | <0.0001 |
| LDL-C (mg/dL) | |||||
| Q1 (0–90) | 9846 | 63.58 | 1 (reference) | 1 (reference) | |
| Q2 (91–110) | 6923 | 44.46 | 0.70 (0.68–0.72) | 0.62 (0.60–0.64) | <0.0001 |
| Q3 (111–131) | 5678 | 37.18 | 0.58 (0.57–0.60) | 0.48 (0.46–0.50) | <0.0001 |
| Q4 (≥132) | 4444 | 28.34 | 0.45 (0.43–0.46) | 0.35 (0.34–0.36) | <0.0001 |
| HDL-C (mg/dL) | |||||
| Q1 (0–48) | 7891 | 50.51 | 1 (reference) | 1 (reference) | |
| Q2 (49–57) | 6022 | 39.24 | 0.78 (0.75–0.80) | 0.84 (0.81–0.86) | <0.0001 |
| Q3 (58–66) | 6046 | 40.0 | 0.79 (0.77–0.82) | 0.83 (0.80–0.86) | <0.0001 |
| Q4 (≥67) | 6932 | 43.53 | 0.86 (0.84–0.89) | 0.87 (0.84–0.90) | <0.0001 |
HCC, hepatocellular carcinoma; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HR, hazard ratio; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus. a Multivariable analysis including age, sex, alcohol consumption, smoking history, regular physical activity, income, BMI, hypertension, DM, and current fenofibrate medication.